The patients with metabolic syndrome were found to have statistically significant higher T stage and grade of bladder cancer.
Raleigh, NC (PRWEB) March 31, 2014
A team of Turkish urology specialists have concluded that bladder cancer is more likely to be of a higher stage and grade in patients who also suffer from metabolic syndrome or diabetes. The results of their new analysis have just been posted on the on Cancer Monthly website. Click here to read the article.
Doctors at the Okmeydani Training and Research Hospital in Istanbul analyzed the cases of more than 500 people who had bladder cancer surgery at their hospital between 2005 and 2011. People with larger waistlines, low HDL cholesterol, high triglycerides, high blood pressure and/or high fasting blood sugar – conditions associated with metabolic syndrome – tended to have more serious forms of bladder cancer.
“The patients with metabolic syndrome were found to have statistically significant higher T stage and grade of bladder cancer,” concludes lead author Dr. Emin Ozbek.
The new study was published in the Asian Pacific Journal of Cancer Prevention. Most of the bladder cancer patients were men and most had urothelial cell carcinoma (also called transitional cell carcinoma), the most common form of bladder cancer among diabetics.
“Although we know that diabetic patients face higher risk of bladder cancer, not much has been written about bladder cancer and metabolic syndrome,” says Alex Strauss, Managing Editor of Cancer Monthly. “This study is yet another reason for people with these kinds of metabolic risk factors to address them now.”
To read the details of the study, including what made the bladder cancer tumors more serious in the metabolic syndrome patients, see Metabolic Syndrome Linked to Bladder Cancer Severity, available now on the Cancer Monthly website.
Ozbek, E et al, “Association between the Metabolic Syndrome and High Tumor Grade and Stage of Primary Urothelial Cell Carcinoma of the Bladder”, 2014, Asian Pacific Journal of Cancer Prevention, pp. 1447-1451. http://www.ncbi.nlm.nih.gov/pubmed/24606481
For over ten years, Cancer Monthly has been the only centralized source of cancer treatment results. Patients can see the actual survival rate, quality-of-life indicators, and other key data for approximately 1,500 different cancer treatments. Cancer Monthly provides timely and ground-breaking news on the causes, diagnoses and treatments of the most common cancers including Bladder, Brain, Breast, Colon, Kidney (Renal), Liver, Lung (NSCLC), Ovarian, Prostate and Rectal Cancers, Melanoma, Mesothelioma, and Non-Hodgkin's Lymphoma. Written for patients and their loved ones, Cancer Monthly helps families make more informed treatment decisions.